key: cord-0975235-qaijif91 authors: Zhang, Ju; Ding, Nan; Ren, Lili; Song, Rui; Chen, Danying; Zhao, Xuesen; Chen, Budong; Han, Junyan; Li, Jiarui; Song, Yangzi; Di, Lin; Han, Kai; Yu, Fengting; Xie, Ruming; Chen, Zhihai; Xie, Wen; Liu, Jingyuan; Cen, Shan; Bi, Yuhai; Wu, Angela R; Zhang, Fujie; Chen, Chen; Zeng, Hui title: COVID-19 reinfection in the presence of neutralizing antibodies date: 2021-01-11 journal: Natl Sci Rev DOI: 10.1093/nsr/nwab006 sha: 92616d4c67a80e109d9dc5038a86f650c257d29e doc_id: 975235 cord_uid: qaijif91 In the face of the coronavirus disease 2019 (COVID-19), strong and long-lasting immunity is required to protect the host from secondary infections. Recent studies revealed potential inadequacy of antibodies against SARS-CoV-2 in some convalescent patients, raising serious concerns about COVID-19 reinfection. Here, from 273 COVID-19 patients, we identified six reinfections based on clinical, phylogenetic, virological, serological, and epidemiological data. During the second episode, we observed re-emergence of COVID-19 symptoms, new pulmonary lesions on CT images, increased viral load, and secondary humoral immune responses. The interval between the two episodes ranged from 19 to 57 days, indicating COVID-19 reinfections could occur after a short recovery period in convalescent patients. More importantly, reinfection occurred not only in patients with inadequate immunity after the primary infection, but also in patients with measurable levels of neutralizing antibodies. This information will aid the implementation of appropriate public health and social measures to control COVID-19, as well as inform vaccine development. , many governments and public health agencies have proposed the idea of an "immunity passport" to help with recovery of community social and economic norms: recovered individuals or those with detectable levels of antibodies against SARS-CoV-2 issued with an immunity passport can be less stringent with lockdown, social distancing, or travel rules, which would enable these individuals to travel or return to work [4, 5] . However, a number of clinical studies have also revealed low titers of antibodies or rapid waning of antibodies against SARS-CoV-2 in convalescent patients [3, 6] , and raised concerns regarding the risks of SARS-CoV-2 reinfection. There have been anecdotal cases independently reported by several groups of patients testing positive for SARS-CoV-2 virus again after recovery, appearing to be recurrence of the infection [7, 8] ; several case studies of reinfection with a second bout of SARS-CoV-2 have also been identified in several countries [9] [10] [11] [12] [13] . However, more evidence is needed to distinguish bona fide reinfection of live exhibited new infected lesions, including patchy ground-glass opacity and consolidation in the chest (Fig. 1B & S2) . These clinical data further support the notion that these patients were reinfected new viruses rather than re-testing positive from the same primary infection. We also performed contact-tracing to assess potential sources of reinfection. an increase in serum antibody titers: for example, case P1 RBD-IgM increased from 1:10 to 1:2560, NP-IgM from 1:20 to 1:80, and NP-IgG from 1:640 to 1:2560 (Fig. 1C & S3, Table S3 ). Since five of the six cases (P1-P5) were infected with the D614G variants in the secondary infection (Table 1) , we also performed microneutralization assays with live virus of both reference SARS-CoV-2 and D614 variants in parallel. Consistent with ELISA data, the samples from case P2 and P4 exhibited low inhibitory dilution 50 (ID50) during the primary and secondary infections; whereas the samples from case P1 and P3 had a certain amount of neutralizing activity against both reference SARS-CoV-2 and D614 variants (Fig. 1C , Table S3 ). Of note, the neutralizing titers against live virus with D614G mutation were 1:18.6 (P1) and >1:64 (P3), respectively (Fig. 1C , Generally, the antibody titer and neutralization ability were in agreement for all reinfection cases (Fig. 1C) , consistent with the literature [18, 19] . In a prior SARS-CoV-2 studies, recovered patients with antibody titers above 1:160 can maintain stable serum antibody levels for up to 148 days [18, 19] . We observed three patients with initially higher antibody titers after recovery (P1, P3, P6) were able to maintain these levels well into the secondary (Fig. 1C) . Furthermore, we observed the neutralizing titers against both SARS-CoV-2 reference strain and D614G variants increased drastically in sera/plasma of case P1 after secondary infection, suggesting that the immune memory response was activated after secondary challenge (Fig. 1C & S3 , Table S3 ). But in all of these cases, P1, P3, and P6, reinfection occurred nonetheless, suggesting that potential COVID-19 reinfections could still occur even in individuals with measurable levels of neutralizing antibodies. Reinfection has been observed in seasonal beta-coronavirus, such as HKU1 and OC4316 [20] ; recently single cases of SARS-CoV-2 reinfection were also reported in Hong Kong, China [9] ; the United States [10] , Ecuador [11] , Belgium [12] , and the Netherlands [13] . Herein, we identified six cases of reinfection. Importantly, the time interval between the two bouts of infection in the present study ranged from 19 to 57 days (Fig. 1A , Table S2 ), indicating that reinfection could occur much earlier than previously suspected. The D614G haplotype was almost non-existent in China during the time of the primary infection, but was found as the variant in five of the six reinfections (Table 1) Table S2 ). Together, these are compelling evidences of the second episode being caused by a new virus, rather than a persistence of the virus causing the first episode. Whether reinfection would occur in an individual is not only determined by the magnitude and duration of that individual's specific immunity, but also varied circumstances of their exposure risk to the virus. The conventional wisdom is that immunity would protect the recovered patients for a long period, and the possibility of reinfection was not considered or taken seriously. Of note, despite strict public health policies and social distancing measurements in Beijing, we still identified multiple cases of SARS-CoV-2 reinfection by monitoring "recovered" patients, suggesting that reinfection might not be a rare event as many previously thought. However, it is not feasible to speculate or derive the population rate or risk of refection based on these data. Considering the escalation of the pandemic in many countries around the world, as well as the continued insufficiency of diagnostic resources in many communities, the risk of re-exposure to SARS-CoV-2 is still high, and the reinfection certainly is a cause for alarm or concern. O R I G It has been proposed that reinfection is a result of inadequate humoral protection against SARS-CoV-2. Consistent with this notion, in the Hong Kong reinfection case the patient did not have adequate amounts of virus-specific antibodies [9] . This is also the case for some patients in this study. However, a recent study revealed that robust neutralizing antibodies to SARS-CoV-2 infection remain relatively stable for several months after infection [19, 21] . Concordant with their findings, we also note substantial titers of neutralizing antibodies before the secondary infection in several patients in this study (Fig. 1C, Table S3 ). This is further evidence that post-convalesce patients with the neutralizing antibodies should not be considered safe against a second bout of infection. Substantial work has been done to investigate the possible changes in SARS-CoV-2 infectivity and immune evasion, and so far, there is little evidence to suggest viral evolution that trends toward increasing viral ability to re-infect or evade antibodies [22] . In this study, the viral genomes sequenced from the secondary infections are found to be of a distinct lineage from that of the primary infection (Table S1) , as confirmed by phylogenetic classification algorithms [23] , and genetic differences between samples were found with high confidence. Further comparisons of complete viral genomes between primary and secondary infections in each paired sample revealed 3-11 SNPs (Table 1) , but interestingly, none of the genomic differences were in the RBD region. In addition, although five viral genomes from the second infection contained a common mutation D614G in the S protein (Table 1) , serum from these patients was still able to neutralize D614G viral variants in vitro (Fig. 1C , Table S3 ) [22] , negating the possibility that these mutations afford the virus with immune escape Clearly, there remains much unknown about COVID-19, and characterizing the underlying mechanism of reinfection could help to inspire development of new vaccines that are safer, more effective, and more protective. That SARS-CoV-2 can cause a second infection in the presence of measurable antibody responses calls into question whether a threshold level of antibody response is required for protection. Vaccine development will need to consider not just whether a response is raised, but also the quantitative level of antibody response raised as an important endpoint for testing and trials. Furthermore, vaccine-induced immunity might be different from natural immunity; vaccines may not induce the same T cell responses as a true SARS-CoV-2 infection does [24] . Studies have accumulated evidence of more broadly dysregulated immune function during viral infection [25] , and consistently, we also observed decreased CD4 + T cell counts in five adult cases, and decreased CD8 + T cell counts in two critical COVID-19 patients (Table S4 & T T T T T T T T T * shows the SNPs validated by PCR-Sanger sequencing approach, which were not covered by enough reads after removing duplicates. N=A or C or G or T. On the founder effect in COVID-19 outbreaks -How many infected travelers may have started them all? National Science Review Antibody responses to SARS-CoV-2 in patients with COVID-19 COVID-19 immunity passports and vaccination certificates: scientific Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19 Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results through a case report Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing Genomic evidence for reinfection with SARS-CoV-2: a case study A case of SARS-CoV-2 reinfection in Ecuador. The Lancet Infectious Diseases Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report Genomic surveillance of COVID-19 cases in Beijing National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine. The protocol of diagnosis and treatment of novel coronavirus pneumonia MINERVA: A facile strategy for SARS-CoV-2 whole genome deep sequencing of clinical samples On the origin and continuing evolution of SARS-CoV-2 Antibody responses and clinical outcomes in adults hospitalized with severe COVID-19: a post hoc analysis of LOTUS China trial Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Direct observation of repeated infections with endemic coronaviruses COVID research updates: Immune responses to coronavirus persist beyond 6 months The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology We thank all health care workers involved in the diagnosis and treatment of the COVID-19 in The authors declare no competing interests. p. 4896F>L T T T C T T T T T T T T G28881A 28881 T T T T T T T A T T T T T4008C 4008 ORF1ab missense variant p.1248F>S T T T T T T T T C T T T T28031C 28031 ORF8 synonymous variant p.46Y T T T T T T T T C T T T C1059T G25217T 25217Intergenic